The North America Antibody Drug Conjugates Market is expected to witness market growth of 13.7% CAGR during the forecast period (2022-2028).
ADCs are anticancer medications that are one of the quickest treatments for cancer patients, with the ability to use the selectivity of monoclonal antibodies against targeted antigens to release potentially lethal chemicals with enhanced activity and lower toxicity than chemotherapies. For cancer treatment, ADCs use antibodies as a vehicle to provide high-potency cytotoxic drug molecules to particular tumor-related antigens. The approval of ten ADCs, including Adcetris and Kadcyla, which are specific for Cd30 and HER2 antigen sites, respectively, demonstrates recent breakthroughs in ADC technology.
The overall share of people aged 65 and up will reach close to 16 percent by 2050. For example, according to the World Health Organization (WHO), by 2050, 80 percent of the world's elderly is expected to be living in OECD countries. The impact of an ageing population on health care systems will be significant.
The antibody-drug conjugate industry in the region is extremely competitive, due to a large number of market players. The rising multiplication of technologically revolutionary technologies in nations such as Canada, the United States, and Mexico, this region is predicted to rapidly control the market. In terms of clinical data, North America is a relatively developed region, and the use of ADCs is considered and accounts for the vast bulk of the established market. Pfizer, for example, acquired Amplyx Pharmaceuticals in April 2021 to create antibody-drug conjugates and other cancer medicines.
For instance, according to the American Cancer Society, an estimated 2, 87,850 new cases of invasive breast cancer is expected to be identified in women in the United States year 2020. In addition, 48,530 cases of in situ breast cancer in women have been investigated, with the number of malignant breast cases predicted to rise in the coming years. Over the forecast period, the growing cases of breast cancer and the existence of good healthcare infrastructure in the region are supposed to drive the antibody drug conjugates market's overall growth.
The US market dominated the North America Antibody Drug Conjugates Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $3,845 Million by 2028. The Canada market is experiencing a CAGR of 16.3% during (2022 - 2028). Additionally, The Mexico market is expected to exhibit a CAGR of 15.2% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
ADCs are anticancer medications that are one of the quickest treatments for cancer patients, with the ability to use the selectivity of monoclonal antibodies against targeted antigens to release potentially lethal chemicals with enhanced activity and lower toxicity than chemotherapies. For cancer treatment, ADCs use antibodies as a vehicle to provide high-potency cytotoxic drug molecules to particular tumor-related antigens. The approval of ten ADCs, including Adcetris and Kadcyla, which are specific for Cd30 and HER2 antigen sites, respectively, demonstrates recent breakthroughs in ADC technology.
The overall share of people aged 65 and up will reach close to 16 percent by 2050. For example, according to the World Health Organization (WHO), by 2050, 80 percent of the world's elderly is expected to be living in OECD countries. The impact of an ageing population on health care systems will be significant.
The antibody-drug conjugate industry in the region is extremely competitive, due to a large number of market players. The rising multiplication of technologically revolutionary technologies in nations such as Canada, the United States, and Mexico, this region is predicted to rapidly control the market. In terms of clinical data, North America is a relatively developed region, and the use of ADCs is considered and accounts for the vast bulk of the established market. Pfizer, for example, acquired Amplyx Pharmaceuticals in April 2021 to create antibody-drug conjugates and other cancer medicines.
For instance, according to the American Cancer Society, an estimated 2, 87,850 new cases of invasive breast cancer is expected to be identified in women in the United States year 2020. In addition, 48,530 cases of in situ breast cancer in women have been investigated, with the number of malignant breast cases predicted to rise in the coming years. Over the forecast period, the growing cases of breast cancer and the existence of good healthcare infrastructure in the region are supposed to drive the antibody drug conjugates market's overall growth.
The US market dominated the North America Antibody Drug Conjugates Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $3,845 Million by 2028. The Canada market is experiencing a CAGR of 16.3% during (2022 - 2028). Additionally, The Mexico market is expected to exhibit a CAGR of 15.2% during (2022 - 2028).
Based on Application, the market is segmented into Breast Cancer, Blood Cancer, Urothelial Cancer & Bladder Cancer, and Others. Based on Technology, the market is segmented into Cleavable Linker, Non-Cleavable Linker, and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., AstraZeneca PLC, GlaxoSmithKline PLC, Pfizer, Inc., Astellas Pharma, Inc., Gilead Sciences, Inc., Seagen, Inc., ADC Therapeutics SA, and Daiichi Sankyo Company, Limited.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Breast Cancer
- Blood Cancer
- Urothelial Cancer & Bladder Cancer
- Others
By Technology
- Cleavable Linker
- Non-Cleavable Linker
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Antibody Drug Conjugates Market by Application
Chapter 5. North America Antibody Drug Conjugates Market by Technology
Chapter 6. North America Antibody Drug Conjugates Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Takeda Pharmaceutical Company Limited
- F. Hoffmann-La Roche Ltd.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Pfizer, Inc.
- Astellas Pharma, Inc.
- Gilead Sciences, Inc.
- Seagen, Inc.
- ADC Therapeutics SA
- Daiichi Sankyo Company, Limited
Methodology
LOADING...
